Literature DB >> 24912813

Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.

Haiyan Zhu1, Xunlong Shi, Dianwen Ju, Hai Huang, Wei Wei, Xiaoying Dong.   

Abstract

The purpose of this study is to investigate the anti-inflammatory effect of thalidomide (Thd) on H1N1-induced acute lung injury in mice. BALB/C mice were infected intranasally with influenza A virus (H1N1) and then treated with Thd at a dose of 100 or 200 mg/kg/day for 7 days. Weight loss and survival of mice were monitored for 14 days after virus challenge, and the serum and lung tissues were collected at 4 days for histological and biochemical analysis. The results showed that Thd significantly improved the survival rate, reduced the infiltration of inflammatory cells and cytokine (e.g., IL-6, TNF-α) and chemokine (e.g., RANTES, IP-10) levels, and inhibited activated p-NFκB p65 in infected mice. These findings suggested that Thd may attenuate H1N1-induced pulmonary injury and thus may find use in the treatment of viral diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24912813     DOI: 10.1007/s10753-014-9943-9

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  17 in total

1.  The protective effect of 3-deoxysappanchalcone on in vitro influenza virus-induced apoptosis and inflammation.

Authors:  Fan Yang; Wei-Ling Zhou; Ai-Lin Liu; Hai-Lin Qin; Simon Ming-Yuen Lee; Yi-Tao Wang; Guan-Hua Du
Journal:  Planta Med       Date:  2012-05-30       Impact factor: 3.352

2.  Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09.

Authors:  A Bradley-Stewart; L Jolly; W Adamson; R Gunson; C Frew-Gillespie; K Templeton; C Aitken; W Carman; S Cameron; C McSharry
Journal:  J Clin Virol       Date:  2013-06-20       Impact factor: 3.168

3.  Expression of RANTES by normal airway epithelial cells after influenza virus A infection.

Authors:  S Matsukura; F Kokubu; H Kubo; T Tomita; H Tokunaga; M Kadokura; T Yamamoto; Y Kuroiwa; T Ohno; H Suzaki; M Adachi
Journal:  Am J Respir Cell Mol Biol       Date:  1998-02       Impact factor: 6.914

Review 4.  Thalidomide: an old drug with new action.

Authors:  V Kumar; S Chhibber
Journal:  J Chemother       Date:  2011-12       Impact factor: 1.714

Review 5.  Pharmacological properties of thalidomide and its analogues.

Authors:  Juan B De Sanctis; Michael Mijares; Alírica Suárez; Reinaldo Compagnone; Jenny Garmendia; Dolores Moreno; Margarita Salazar-Bookaman
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2010-06

6.  What happened after the initial global spread of pandemic human influenza virus A (H1N1)? A population genetics approach.

Authors:  Fernando Martinez-Hernandez; Diego Emiliano Jimenez-Gonzalez; Arony Martinez-Flores; Guiehdani Villalobos-Castillejos; Gilberto Vaughan; Simon Kawa-Karasik; Ana Flisser; Pablo Maravilla; Mirza Romero-Valdovinos
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

Review 7.  Thalidomide-a notorious sedative to a wonder anticancer drug.

Authors:  Shuang Zhou; Fengfei Wang; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 8.  Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy.

Authors:  Stephan Ludwig; Oliver Planz
Journal:  Biol Chem       Date:  2008-10       Impact factor: 3.915

9.  An improved embryonated chicken egg model for the evaluation of antiviral drugs against influenza A virus.

Authors:  Ji-Xi Wang; Jing-Yu Zhou; Qing-Wei Yang; Yang Chen; Xin Li; Ying-Ai Piao; Hong-Yuan Li
Journal:  J Virol Methods       Date:  2008-09-16       Impact factor: 2.014

10.  Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury.

Authors:  Wei Wang; Penghui Yang; Ying Zhong; Zhongpeng Zhao; Li Xing; Yan Zhao; Zhen Zou; Yanli Zhang; Chenggang Li; Taisheng Li; Chen Wang; Zhong Wang; Xuezhong Yu; Bin Cao; Xiang Gao; Josef M Penninger; Xiliang Wang; Chengyu Jiang
Journal:  Cell Res       Date:  2013-02-19       Impact factor: 25.617

View more
  17 in total

1.  Effects of Gui Zhi Ma Huang Ge Ban Tang on the TLR7 Pathway in Influenza Virus Infected Mouse Lungs in a Cold Environment.

Authors:  Hong-Qiong Qin; Shan-Shan Shi; Ying-Jie Fu; Yu-Qi Yan; Sha Wu; Xiao-Long Tang; Xiao-Yin Chen; Guang-Hui Hou; Zhen-You Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-23       Impact factor: 2.629

Review 2.  Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.

Authors:  Isabella Orienti; Giovanna Angela Gentilomi; Giovanna Farruggia
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

3.  Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?

Authors:  Athar Khalil; Amina Kamar; Georges Nemer
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561

4.  Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.

Authors:  Chengshui Chen; Feng Qi; Keqing Shi; Yuping Li; Ji Li; Yongping Chen; Jingye Pan; Tieli Zhou; Xiangyang Lin; Jinsan Zhang; Yongde Luo; Xiaokun Li; Jinglin Xia
Journal:  Clin Transl Med       Date:  2020-06-04

Review 5.  Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.

Authors:  Sandra Söderholm; Yu Fu; Lana Gaelings; Sergey Belanov; Laxman Yetukuri; Mikhail Berlinkov; Anton V Cheltsov; Simon Anders; Tero Aittokallio; Tuula A Nyman; Sampsa Matikainen; Denis E Kainov
Journal:  Viruses       Date:  2016-09-29       Impact factor: 5.048

Review 6.  A Review of SARS-CoV-2 and the Ongoing Clinical Trials.

Authors:  Yung-Fang Tu; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Yi-Ying Lin; Yung-Hung Luo; Yi-Tsung Lin; Wei-Yi Lai; De-Ming Yang; Shih-Jie Chou; Yi-Ping Yang; Mong-Lien Wang; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

Review 7.  Immunotherapeutic approaches to curtail COVID-19.

Authors:  Hajar Owji; Manica Negahdaripour; Nasim Hajighahramani
Journal:  Int Immunopharmacol       Date:  2020-08-21       Impact factor: 4.932

Review 8.  Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review.

Authors:  Courtney M Campbell; Avirup Guha; Tamanna Haque; Tomas G Neilan; Daniel Addison
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

9.  Thal protects against paraquat-induced lung injury through a microRNA-141/HDAC6/IκBα-NF-κB axis in rat and cell models.

Authors:  Fenshuang Zheng; Junbo Zhu; Wei Zhang; Yangshan Fu; Zhaoheng Lin
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-10-14       Impact factor: 4.080

10.  Emerging pharmacological therapies for ARDS: COVID-19 and beyond.

Authors:  Shahd Horie; Bairbre McNicholas; Emanuele Rezoagli; Tài Pham; Ger Curley; Danny McAuley; Cecilia O'Kane; Alistair Nichol; Claudia Dos Santos; Patricia R M Rocco; Giacomo Bellani; John G Laffey
Journal:  Intensive Care Med       Date:  2020-07-11       Impact factor: 41.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.